{
    "Trade/Device Name(s)": [
        "HE4 EIA kit",
        "Fujirebio Diagnostics Tumor Marker Control"
    ],
    "Submitter Information": "Fujirebio Diagnostics, Inc.",
    "510(k) Number": "K103676",
    "Predicate Device Reference 510(k) Number(s)": [
        "K072939",
        "K101809"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "OIU",
        "JJY"
    ],
    "Summary Letter Date": "July 7, 2011",
    "Summary Letter Received Date": "July 8, 2011",
    "Submission Date": "July 18, 2011",
    "Regulation Number(s)": [
        "21 CFR 866.6010",
        "21 CFR 862.1660"
    ],
    "Regulation Name(s)": [
        "Tumor-associated Antigen Immunological Test",
        "Quality control material (assayed and unassayed)"
    ],
    "Analyte Class(es)": [
        "immunology",
        "cancer molecular"
    ],
    "Analyte(s)": [
        "HE4 (Human Epididymis Protein 4)",
        "AFP (Alpha-Fetoprotein)",
        "CA 15-3",
        "CA 19-9",
        "CA 125",
        "CEA (Carcinoembryonic Antigen)",
        "Ferritin",
        "PSA (Prostate Specific Antigen)",
        "Free PSA"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Enzyme immunometric assay"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Control",
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for Fujirebio Diagnostics Tumor Marker Control as assayed control serum for use with HE4 EIA kit to monitor laboratory precision in tumor marker assays.",
    "Indications for Use Summary": "Fujirebio Diagnostics Tumor Marker Control is intended as an assayed control serum to monitor the precision of laboratory testing procedures for listed analytes; HE4 EIA is intended for quantitative determination of HE4 in human serum as an aid in monitoring recurrence or progression of epithelial ovarian cancer.",
    "fda_folder": "Immunology"
}